Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Annual shareholder meeting highlights
-
LONDON and NEW YORK, Jan. 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of...
-
PharmAla inks contract with Ostfold Hospital Trust in Oslo to supply clinical trial in exchange for both cash and a data license
-
Initial AX-0810 data show no safety signals after 4 weeks of dosing and pharmacokinetics consistent with non-clinical data; Phase 1 enrollment and dosing in healthy volunteers ongoing with target...
-
Science 37 Named Finalist for 2026 SCOPE Participant Engagement and Site Innovation Awards.
-
-
Fentanyl designation Response
-
First Patient Dosed with Intranasal Foralumab in Randomized, Placebo-Controlled Phase 2 TrialBuilds on Recent Evidence of Persistent Neuroinflammation in Alzheimer’s Patients Treated with Anti-Amyloid...
-
MoonLake Immunotherapeutics Hit with Securities Fraud Class Action after Drug Trial Results – Contact BFA Law if You Suffered Losses
-
MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today...